307 related articles for article (PubMed ID: 10076535)
1. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells.
Wang LG; Liu XM; Budman DR; Kreis W
Biochem Pharmacol; 1999 Oct; 58(7):1115-21. PubMed ID: 10484069
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
Song LN; Coghlan M; Gelmann EP
Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
[TBL] [Abstract][Full Text] [Related]
5. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
8. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
9. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
11. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
12. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
[TBL] [Abstract][Full Text] [Related]
13. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Culig Z; Hobisch A; Hittmair A; Cronauer MV; Radmayr C; Zhang J; Bartsch G; Klocker H
Prostate; 1997 Jul; 32(2):106-14. PubMed ID: 9215398
[TBL] [Abstract][Full Text] [Related]
16. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
17. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
[TBL] [Abstract][Full Text] [Related]
18. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
[TBL] [Abstract][Full Text] [Related]
19. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects.
Térouanne B; Tahiri B; Georget V; Belon C; Poujol N; Avances C; Orio F; Balaguer P; Sultan C
Mol Cell Endocrinol; 2000 Feb; 160(1-2):39-49. PubMed ID: 10715537
[TBL] [Abstract][Full Text] [Related]
20. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.
Norlén BJ; Andersson SB; Björk P; Gunnarsson PO; Fritjofsson A
J Urol; 1988 Nov; 140(5):1058-62. PubMed ID: 3172360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
